Abstracts tagged "Inflammation"

Abstract Number: 0494 • ACR Convergence 2024
Usefulness of the Neutrophil-to-Lymphocyte Ratio, the Platelet-to-Lymphocyte Ratio and the Systemic Immune Inflammatory Index in Assessing Disease Activity in Rheumatoid Arthritis Patients
Yelitza Cecilia Velarde Mejia¹, Ventura Mejia², guillermo velarde² and Graciela Alarcon³, ¹Hncase, Arequipa, Peru, ²UNIVERSIDAD NACIONAL DE SAN AGUSTIN, arequipa, Peru, ³The University of Alabama at Birmingham, Oakland, CA
Background/Purpose: Rheumatoid arthritis (RA) causes systemic inflammation that leads to specific changes in the patients’ blood cells; this offers the opportunity to measure inflammatory activity…
Abstract Number: 0833 • ACR Convergence 2024
Novel Loss of Function Variants in the Death Domain of Tumor Necrosis Factor Superfamily Receptor 1A (TNFRSF1A) in Children with Systemic Juvenile Idiopathic Arthritis (sJIA)
Anthony Cruz¹, Hiroto Nakano², Sophia Chou³, Marissa Krantz⁴, Tianmin Fu⁵, Davide Randazzo⁶, Zuoming deng⁷, Hao Wu⁸ and Michael Ombrello⁹, and INCHARGE Consortium, ¹National Institutes of Health, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³National Institutes of Health, Rockville, MD, ⁴University of Rochester, Rochester, NY, ⁵Ohio State University College of Medicine, Columbus, OH, ⁶NIAMS/NIH, Bethesda, MD, ⁷National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ⁸Harvard Medical School, Boston, MA, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is an inflammatory condition characterized by recurring fevers, arthritis and hyperinflammation, but its exact etiology is unknown. Tumor necrosis…
Abstract Number: 0944 • ACR Convergence 2024
Targeting Defective Macrophages to Restore Resolution of Inflammation in Rheumatoid Arthritis -Perspectives for an Autologous Secretome Therapy
Melanie Couturier¹, Francis Bonnefoy², emilie Gaiffe³, Charline Vauchy⁴, Suzanne Behlke², ERIC TOUSSIROT⁵ and Sylvain Perruche², ¹1MED’INN’Pharma, F-25000 Besançon, France, Besançon, France, ²MED’INN’Pharma, F-25000 Besançon, France, Besançon, France, ³INSERM CIC -1431 CHU Besançon, France, Besançon, France, ⁴INSERM CIC-1431, CHU de Besançon, Besancon, France, Besançon, France, ⁵university hospital of BESANCON, besancon, France
Background/Purpose: Impaired macrophage efferocytosis, a key hallmark of failed inflammation resolution, is reported in many immune-mediated inflammatory diseases, including in Rheumatoid Arthritis (RA). Hence the…
Abstract Number: 1512 • ACR Convergence 2024
Association Between the Systemic Immune Inflammatory Index (Sll) and All-cause Mortality in Critically Ill Patients with Rheumatoid Arthritis
Yunfeng Dai and Zhihan Chen, Fujian Medical University, Fuzhou City, Fujian, China (People's Republic)
Background/Purpose: The systemic immune-inflammation index (SII) has been linked to inflammatory and immune responses, with research indicating its impact on rheumatoid arthritis (RA). However, its…
Abstract Number: 1799 • ACR Convergence 2024
In VitroEvidence for the Restoration of Glucocorticoid Sensitivity by Toll-Like Receptor 7 and 8 Inhibition in Systemic Lupus Erythematosus
Jia Xin Chow¹, Rochelle Sherlock², Taylah Bennett², Eric Morand³ and Sarah Jones², ¹Monash University, Melbourne, Victoria, Australia, ²Monash University, Melbourne, Australia, ³School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: The strategy of inhibiting toll-like receptors (TLR) 7 and 8 is being evaluated in clinical trials in systemic lupus erythematosus (SLE) to assess its…
Abstract Number: 2010 • ACR Convergence 2024
The Influence of Treat-to-target Urate Lowering Therapy and Anti-inflammatory Prophylaxis on Circulating Measures of Inflammation in Gout
Austin Wheeler¹, Tanner Ourada², Michael Duryee¹, Bryant England¹, Richard Reynolds³, James O'Dell¹, Jeff Newcomb¹, Michael Pillinger⁴, Robert Terkeltaub⁵, Ryan Ferguson⁶, Mary Brophy⁶, Tony Merriman⁷ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska-Medical Center: College of Medicine, Omaha, NE, ³University of Alabama at Birmingham, Birmingham, AL, ⁴New York University Grossman School of Medicine, New York,, NY, ⁵Retired, San Diego, CA, ⁶Veterans Affairs, Boston, MA, ⁷University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Gout is the most common inflammatory arthritis worldwide and is associated with substantial cardiometabolic morbidity and mortality. In the STOP Gout trial (O’Dell JR…
Abstract Number: 2536 • ACR Convergence 2024
Trans-Disease Microbial Biomarkers of Protection and Pathogenesis in Autoimmune Conditions: Results from the AMP AIM Consortium
Kevin Bu¹, Rebecca Blank², Adam Cantor¹, Alba Boix-Amoros³, Jose Scher⁴ and Jose Clemente¹, and Accelerating Medicines Partnership and Immune-Mediated Diseases Network (AMP AIM), ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²NYU, New York, NY, ³Icahn School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY
Background/Purpose: Autoimmune and immune-mediated diseases (AIMDs) affect over 20 million Americans. Although AIMDs have distinct symptomatology, there is significant overlap in their treatment, suggesting overlap…
Abstract Number: 0147 • ACR Convergence 2024
Clinical Characteristics and Biomarkers Associated with Detectable High-Sensitivity Cardiac Troponin in Patients with Rheumatoid Arthritis
Ilana Usiskin¹, Mary Jeffway¹, Feng Liu¹, Nancy Shadick¹, Michael Weinblatt², Brittany Weber³ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ³Brigham and Women's Hospital, DEDHAM, MA
Background/Purpose: General population-based cardiovascular (CV) risk estimators are known to underestimate CV risk in RA. High-sensitivity cardiac troponin T (hs-cTnT), typically measured during a work-up…
Abstract Number: 0515 • ACR Convergence 2024
Scavenging Isolevuglandins with 2-HOBA Decreases In Vitro Neutrophil Extracellular Traps in Cells from Patients with Rheumatoid Arthritis
Olivia Posey, Anastasiia Phothisane, Phicharmon Kulapatana and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Neutrophils contribute to the innate immune response of killing pathogens through the formation of neutrophil extracellular traps (NETs), which is also called NETosis. NETosis…
Abstract Number: 0834 • ACR Convergence 2024
Evolution of Lung Inflammation in a Mouse Model of Chronic/Recurrent Macrophage Activation Syndrome
Richard Chhaing, Natsumi Inoue, Jana Latayan and grant schulert, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis-associated lung disease (SJIA-LD) is a life-threatening complication and associated in >80% of cases with macrophage activation syndrome (MAS); however, the…
Abstract Number: 0951 • ACR Convergence 2024
A Feedback Loop Involving mtDNA, Platelets and Neutrophil Extracellular Traps Amplifies Inflammation in Systemic Sclerosis
Stavros Giaglis¹, Diego Kyburz² and Ulrich Walker³, ¹Experimental Rheumatology Laboratory, University of Basel, Basel, Switzerland, ²University Hospital Basel, Basel, Switzerland, ³Basel University Hospital, Basel, Switzerland
Background/Purpose: Mitochondria are essential eucaryotic cell organelles with several bacterial features, such as a double-stranded circular genome with hypomethylated CpG areas (1). A fundamental role of…
Abstract Number: 1567 • ACR Convergence 2024
Systemic Sclerosis Is Associated with Sub-Clinical Abnormalities in Myocardial Energetics, Perfusion and Increased Fibrosis
Chin Yit Soo¹, Nicholas Jex², Stefano Di Donato³, Lucy Elizabeth Thornton⁴, Vishal Kakkar⁵, Riccardo Bixio⁶, Raluca Tomoaia¹, Thomas Anderton², May Lwin², Christel Kamani², Amrit Chowdhary², Henry Procter¹, Sharmaine Thirunavukarasu¹, Sindhoora Kotha², Marilena Giannoudi², Eylem Levelt², Sven Plein¹, Francesco Delgado⁶ and Lesley-Anne Bissell⁷, ¹Multidisciplinary Cardiovascular Research Centre and Biomedical Imaging Science Department, University of Leeds, Leeds, United Kingdom., Leeds, England, United Kingdom, ²Multidisciplinary Cardiovascular Research Centre and Biomedical Imaging Science Department, University of Leeds, Leeds, United Kingdom., Leeds, United Kingdom, ³1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, United Kingdom, ⁴1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, ⁵University of Leeds, Leeds, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom., Leeds, United Kingdom, ⁷Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Primary cardiac involvement in systemic sclerosis (SSc) is heterogenous, poorly defined and associated with significant cardiac morbidity and mortality. The underlying mechanism is not…
Abstract Number: 1810 • ACR Convergence 2024
Modulation of Type I Interferon Signaling by Anifrolumab Alters the Spatial Immune Landscape in Cutaneous Lupus Erythematosus
Ksenia Anufrieva¹, Rochelle Castillo², Ce Gao², Jessica Liu², Neda Shahriari², Kimberly Hashemi², Dustin Taylor³, Rachael Rowley², Elizabeth Rainone², Avery LaChance², Rachel Gate⁴, ilya Korsunsky², Ruth Ann Vleugels⁵ and Kevin Wei⁶, ¹BWH, Cambridge, MA, ²Brigham and Women's Hospital, Boston, MA, ³Vanderbilt University Medical Center, Nashville, TN, ⁴10x Genomics, Pleasanton, CA, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Brigham and Women's Hospital at Harvard Medical School, Boston, MA
Background/Purpose: Reliable and effective treatments for refractory cutaneous lupus erythematosus (CLE) remained elusive until the arrival of anifrolumab, a monoclonal antibody targeting the type I…
Abstract Number: 2032 • ACR Convergence 2024
A Systematic Review of Treatment Strategies in VEXAS Syndrome
Aviraag Vijaya Prakash¹, Jose Garcia², Anurag Goel³, Vinit Gilvaz⁴ and Raveena Midha⁵, ¹Saint Vincent Hospital, Department of Internal Medicine, Worcester, MA, ²Brown University, East Greenwich, RI, ³The Warren Alpert Medical School of Brown University, Providence, RI, ⁴The Warren Alpert Medical School of Brown University, East Providence, RI, ⁵Kent Hospital/Brown University, Warwick, RI
Background/Purpose: VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome, first described in 2020, is an autoinflammatory condition characterized by somatic mutations in the UBA1 gene.…
Abstract Number: 2557 • ACR Convergence 2024
The Relation of Colchicine to Knee/hip Replacement Among People with Gout in a Population-based Cohort Study
Zhiqiang Wang¹, Sarah Tilley², Christine Peloquin², Eva Petrow³, Margaret Clancy² and Tuhina Neogi², ¹Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, Guangdong, China (People's Republic), ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³Boston Medical Center, Boston, MA
Background/Purpose: Colchicine, an anti-inflammatory drug commonly used in gout, has been associated with a lower incidence of total knee/hip replacement compared to placebo among participants…

« Previous Page
1
…
5
6
7
8
9
…
58
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].